Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
Abstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing t...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-022-03592-4 |
| _version_ | 1828144439667720192 |
|---|---|
| author | Paolo A. Ascierto Sanjiv S. Agarwala Christian Blank Corrado Caracò Richard D. Carvajal Marc S. Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Jean-Jacques Grob Omid Hamid Michelle Krogsgaard Roger S. Lo Amanda W. Lund Gabriele Madonna Olivier Michielin Bart Neyns Iman Osman Solange Peters Poulikos I. Poulikakos Sergio A. Quezada Bradley Reinfeld Laurence Zitvogel Igor Puzanov Magdalena Thurin |
| author_facet | Paolo A. Ascierto Sanjiv S. Agarwala Christian Blank Corrado Caracò Richard D. Carvajal Marc S. Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Jean-Jacques Grob Omid Hamid Michelle Krogsgaard Roger S. Lo Amanda W. Lund Gabriele Madonna Olivier Michielin Bart Neyns Iman Osman Solange Peters Poulikos I. Poulikakos Sergio A. Quezada Bradley Reinfeld Laurence Zitvogel Igor Puzanov Magdalena Thurin |
| author_sort | Paolo A. Ascierto |
| collection | DOAJ |
| description | Abstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic theràapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients. |
| first_indexed | 2024-04-11T20:15:20Z |
| format | Article |
| id | doaj.art-eceaa54ada8b4252a49fcbe967456d2a |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-04-11T20:15:20Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-eceaa54ada8b4252a49fcbe967456d2a2022-12-22T04:04:59ZengBMCJournal of Translational Medicine1479-58762022-09-0120112110.1186/s12967-022-03592-4Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)Paolo A. Ascierto0Sanjiv S. Agarwala1Christian Blank2Corrado Caracò3Richard D. Carvajal4Marc S. Ernstoff5Soldano Ferrone6Bernard A. Fox7Thomas F. Gajewski8Claus Garbe9Jean-Jacques Grob10Omid Hamid11Michelle Krogsgaard12Roger S. Lo13Amanda W. Lund14Gabriele Madonna15Olivier Michielin16Bart Neyns17Iman Osman18Solange Peters19Poulikos I. Poulikakos20Sergio A. Quezada21Bradley Reinfeld22Laurence Zitvogel23Igor Puzanov24Magdalena Thurin25Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS “Fondazione G. Pascale”Hematology & Oncology, Temple University and Cancer Expert NowNetherlands Cancer InstituteDivision of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori “Fondazione Pascale” IRCCSDivision of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical CenterDevelopmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCIDepartment of Surgery, Massachusetts General Hospital, Harvard Medical SchoolEarle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer InstituteDepartment of Pathology and Department of Medicine (Section of Hematology/Oncology), University of ChicagoCenter for Dermato-Oncology, University-Department of DermatologyDermatology Department, Hopital de La TimoneMedical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai AffiliateNew York Grossman School of Medicine, New York University LangoneJonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLARonald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of MedicineDepartment of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV)Medical Oncology, Universitair Ziekenhuis BrusselNew York University Langone Medical CenterUNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific CoordinatorDepartment of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer InstituteCancer Immunology Unit, Research Department of Hematology, University College London Cancer InstituteDepartment of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt UniversityTumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERMDepartment of MedicineCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCIAbstract Advances in immune checkpoint and combination therapy have led to improvement in overall survival for patients with advanced melanoma. Improved understanding of the tumor, tumor microenvironment and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. Combination modalities with other immunotherapy agents, chemotherapy, radiotherapy, electrochemotherapy are also being explored to overcome resistance and to potentiate the immune response. In addition, novel approaches such as adoptive cell therapy, oncogenic viruses, vaccines and different strategies of drug administration including sequential, or combination treatment are being tested. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic theràapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers, but they have yet to be fully characterized and implemented clinically. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. Overall, the future research efforts in melanoma therapeutics and translational research should focus on several aspects including: (a) developing robust biomarkers to predict efficacy of therapeutic modalities to guide clinical decision-making and optimize treatment regimens, (b) identifying mechanisms of therapeutic resistance to immune checkpoint inhibitors that are potentially actionable, (c) identifying biomarkers to predict therapy-induced adverse events, and (d) studying mechanism of actions of therapeutic agents and developing algorithms to optimize combination treatments. During the Melanoma Bridge meeting (December 2nd-4th, 2021, Naples, Italy) discussions focused on the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine as well as the impact of COVID-19 pandemic on management of melanoma patients.https://doi.org/10.1186/s12967-022-03592-4MelanomaImmunotherapyAnti-PD-1Anti-CTLA-4Target therapyBiomarkers |
| spellingShingle | Paolo A. Ascierto Sanjiv S. Agarwala Christian Blank Corrado Caracò Richard D. Carvajal Marc S. Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Jean-Jacques Grob Omid Hamid Michelle Krogsgaard Roger S. Lo Amanda W. Lund Gabriele Madonna Olivier Michielin Bart Neyns Iman Osman Solange Peters Poulikos I. Poulikakos Sergio A. Quezada Bradley Reinfeld Laurence Zitvogel Igor Puzanov Magdalena Thurin Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) Journal of Translational Medicine Melanoma Immunotherapy Anti-PD-1 Anti-CTLA-4 Target therapy Biomarkers |
| title | Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) |
| title_full | Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) |
| title_fullStr | Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) |
| title_full_unstemmed | Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) |
| title_short | Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy) |
| title_sort | perspectives in melanoma meeting report from the melanoma bridge december 2nd 4th 2021 italy |
| topic | Melanoma Immunotherapy Anti-PD-1 Anti-CTLA-4 Target therapy Biomarkers |
| url | https://doi.org/10.1186/s12967-022-03592-4 |
| work_keys_str_mv | AT paoloaascierto perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT sanjivsagarwala perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT christianblank perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT corradocaraco perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT richarddcarvajal perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT marcsernstoff perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT soldanoferrone perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT bernardafox perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT thomasfgajewski perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT clausgarbe perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT jeanjacquesgrob perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT omidhamid perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT michellekrogsgaard perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT rogerslo perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT amandawlund perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT gabrielemadonna perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT oliviermichielin perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT bartneyns perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT imanosman perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT solangepeters perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT poulikosipoulikakos perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT sergioaquezada perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT bradleyreinfeld perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT laurencezitvogel perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT igorpuzanov perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy AT magdalenathurin perspectivesinmelanomameetingreportfromthemelanomabridgedecember2nd4th2021italy |